Cyclacel Pharma (CYCC) Reports Q4 Loss of $0.62
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Cyclacel Pharma (CYCC) Says Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors
March 25, 2019 7:03 AM EDTCyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, highlighted a paper from independent investigators titled Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone ReceptorPositive Metastatic Breast Cancer published in the most recent edition of the Journal of Clinical Oncology (Turner N et al, 2019... More
